TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05544539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone-Based Agent
Description: In the study group Ozone oil was placed inside the socket of the extracted tooth following suturing of the flap

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the control group Ozone oil syringe was placed inside the socket of the extracted tooth without applying the oil
Study: NCT05952908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proficiency-Based Progression simulation training
Description: The simulation-based training curriculum is delivered - with proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
Study: NCT06004414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based Cognitive Behavioral Therapy (CBT)
Description: SilverCloud is organized into eight core modules that follow evidence-based principles of CBT, along with six additional modules that can be prescribed by the clinician to address a participant's specific needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Psychotherapy with a licensed clinician in the school-based health center.
Study: NCT04184323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EX-527 (Selisistat)
Description: EX-527 is a specific inhibitor of the histone deacetylase Sirtuin-1 (SirT1). It is being given to reverse the effects of endometriosis, namely progesterone resistance, that is thought to interfere with the establishment of pregnancy in women with endometriosis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: We will use the same vehicle for producing the active drug such as maltose without any hormones or active components
Study: NCT05343338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium
Description: After dissolving sivelestat sodium with 0.9% sodium chloride injection, dilute the 1-day dose (4.8 mg/kg) with 50 mL of 0.9% sodium chloride injection and continue intravenously at a rate of 0.2 mg/kg/h for administration. The start time of administration was after induction of anesthesia, and at the same time, the extracorporeal circulation circuit is prefilled with 100 mg. The end time is 48 hours after admission to the ICU.
Study: NCT04836936

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Auriculotherapy cryopuncture device without nitrogen gas
Description: Auriculotherapy cryopuncture device without nitrogen gas will be administered. Application of this placebo device will be performed in the same manner as the treatment, but without the expulsion of nitrogen gas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy cryopuncture device with nitrogen gas
Description: Auriculotherapy cryopuncture device with nitrogen gas will be administered. The tip of the cryopuncture will be sanitized and placed on each treatment point of the ear, releasing a spurt of nitrogen gas for 2 seconds on each point (6 points total).
Study: NCT06340321

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic flexibility in the fasted state
Description: Measured at baseline during the InSight study (2008-2009). Calculated as the respiratory exchange ratio in the fasting state adjusted for the circulating concentrations of free fatty acids

Intervention type: OTHER
Intervention: Metabolic flexibility in euglycemic-hyperinsulinemic clamp
Description: Measured at baseline during the InSight study (2008-2009). Calculated as the change in respiratory exchange ratio adjusted for glucose disposal rate

Intervention type: OTHER
Intervention: Metabolic flexibility in the metabolic chamber
Description: Measured at baseline during the InSight study (2008-2009). Calculated as the difference between awake respiratory exchange ratio (from 8 a.m. to 11 p.m.) and sleeping respiratory exchange ratio during a 23-hour stay in the metabolic chamber
Study: NCT06384950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ChatGPT
Description: Patients receive additional education using a GPT-3.5-based educational robot on top of the traditional education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient education with traditional methods.
Description: Patients receive standard traditional education procedures.
Study: NCT06371131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right -stellate ganglion block
Description: The experimental group was given right stellate ganglion block 30 minutes before anesthesia induction
Study: NCT06579274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: Parecoxib (Dynastat) 40 mg solution for injection is for intravenous administration. Parecoxib may be given as an intravenous injection for 30 minutes directly into a vein or through an intravenous infusion set.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous injection can be administered quickly and directly into a vein or through an intravenous infusion set.
Study: NCT05295966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive therapy
Description: Cognitive therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Description: Cognitive therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiocognitive Integration
Description: Physiocognitive Integration
Study: NCT05952908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional simulation training
Description: The simulation-based training curriculum is delivered - without proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
Study: NCT06378918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: puncture
Description: Local anesthesia is previously carried out with 2-5 cc of 1% lidocaine. The puncture is then carried out using a 16 gauge needle. Antibiotic coverage will be offered. A work stoppage is recommended until the day after the puncture/aspiration but the duration is left to the discretion of the surgeon. A visit is systematically realised 15 days after the puncture/aspiration with a recommendation for earlier consultation in the event of persistence of redness, discharge, pain or onset of fever. If these symptoms recur or persist, it is recommended to make an incision with packing. In the event of fistulization following the puncture, associated with discharge and skin necrosis, local nursing care is recommended. The definitive resection procedure is then planned 4 to 6 weeks after the puncture/aspiration if the evolution is favorable.
Study: NCT06211400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise
Description: 6-week supervised whole body vibration exercise programme (training sessions three times per week lasting 10 min) alongside a lifestyle education programme
Study: NCT06384248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC004
Description: LTC004,45μg/kg,IV,Day 1,Q3W;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC004
Description: LTC004,45μg/kg,IV,Day 1,Q3W;
Study: NCT06378918

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: incision of the abscess
Description: This is carried out according to the habits of the department: in the operating room under general or local anesthesia or in consultation (or emergencies) under local anesthesia. The procedure is carried out on an outpatient basis but, if necessary, short-term hospitalization is carried out. Daily drying is then carried out with nursing care at home until healing. A work stoppage is recommended for a period of approximately 10 days. A visit is systematically realised 15 days after the incision with a recommendation for earlier consultation in the event of persistence of redness, discharge, pain or onset of fever. If these symptoms recur or persist, it is recommended to make an incision with packing. The definitive resection procedure is then planned 4 to 6 weeks after the initial operation if the evolution is favorable.
Study: NCT05373355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablets
Description: Oral tablets administered at different doses BID daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablets
Description: Oral tablets administered at different doses BID daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TLL018 tablets
Description: Oral tablets administered at different doses BID daily for 12 weeks.
Study: NCT05580666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Oral Tablet
Description: Antimicrobial therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Inert ingredients
Study: NCT05867654

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin-clavulanate 875mg/125mg q12hrs
Description: Oral antibiotic used based on indication

Intervention type: DRUG
Group type: OTHER
Intervention: oral clindamycin 300mg q6hrs
Description: Oral antibiotic used based on indication

Intervention type: DRUG
Group type: OTHER
Intervention: Levofloxacin 750mg QID
Description: Oral antibiotic used based on indication
Study: NCT05120115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight belt
Description: Wearing belt around waist with various weights attached.
Study: NCT05001360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XBI-302 + Nivolumab
Description: After gut preparation, a single dose of FMT will be performed via oral administration. Subsequently, nine combined treatment cycles that composed of anti-PD-1 infusions (Nivolumab at 240 mg, q2w) and additional FMT capsules, and 3 single treatment cycles of anti-PD-1 infusions will be administered.
Study: NCT06187740

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiotherapy
Description: Thoracic radiotherapy should begin within 42 days after the end of the last chemotherapy at an initial dose of 30 Gy in 10 fractions (3 patients).~Dose escalation will start after acceptable safety was observed, first at: 35 Gy/10 Fx(3 patients), then to the next dose group: 40 Gy/10 Fx(22 patients). Radiotherapy was administered between two immunotherapy doses (3 weeks interval) to avoid thoracic radiotherapy on the same day with immunotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiotherapy
Description: Thoracic radiotherapy should begin within 42 days after the end of the last chemotherapy at an initial dose of 30 Gy in 10 fractions (3 patients).~Dose escalation will start after acceptable safety was observed, first at: 35 Gy/10 Fx(3 patients), then to the next dose group: 40 Gy/10 Fx(22 patients). Radiotherapy was administered between two immunotherapy doses (3 weeks interval) to avoid thoracic radiotherapy on the same day with immunotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiotherapy
Description: Thoracic radiotherapy should begin within 42 days after the end of the last chemotherapy at an initial dose of 30 Gy in 10 fractions (3 patients).~Dose escalation will start after acceptable safety was observed, first at: 35 Gy/10 Fx(3 patients), then to the next dose group: 40 Gy/10 Fx(22 patients). Radiotherapy was administered between two immunotherapy doses (3 weeks interval) to avoid thoracic radiotherapy on the same day with immunotherapy.
Study: NCT04782557

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EUS-guided portal vein and hepatic vein aspiration
Description: EUS-guided portal vein and hepatic vein aspiration
Study: NCT05895110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus vaccine (CHO Cells)
Description: The experimental vaccine dose used in this study is 25μg/0.5mL. All subjects recruited should have received two doses of novel Coronavirus inactivated vaccine on the market for 6-9 months, and all eligible subjects will receive one dose of recombinant Novel Coronavirus vaccine (CHO cells).
Study: NCT04843787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV213
Description: SLV213 oral capsule (200mg) BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV213
Description: SLV213 oral capsule (200mg) BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV213
Description: SLV213 oral capsule (400mg) BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV213
Description: SLV213 oral capsule (400mg) BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV213
Description: SLV213 oral capsule (800mg) QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV213
Description: SLV213 oral capsule (800mg) QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule (200mg) BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule (200mg) BID
Study: NCT06032377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy for sleep, anxiety, and depression
Description: This intervention addresses insomnia, anxiety and depression via modules covering all the core CBTi components: psychoeducation about insomnia, relaxation, cognitive restructuring, stimulus control, sleep restriction and stress management; as well as psychoeducation about anxiety and low mood, behavioral activation strategies, and strategies to better manage ruminations. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education about healthy nutrition habits and communication in older age
Description: This intervention addresses healthy nutrition habits as well as communication and aging. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings
Study: NCT06133751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: black chokeberry (Aronia melanocarpa)
Description: Black chokeberry capsules standardized for anthocyanin compounds

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Chokeberry fiber placebo capsules
Study: NCT05069831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abrocitinib
Description: Abrocitinib daily for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abrocitinib
Description: Abrocitinib daily for 4 months
Study: NCT05890989

Intervention type: DIAGNOSTIC_TEST
Intervention: EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT
Description: EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT OF THE PARTICIPANTS WAS MADE.
Study: NCT05667363

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Digital Intervention
Description: Digital therapeutics are consist of a smartphone app and an intelligent medication recorder. The intelligent medication recorder can automatically record medication using data and reminds patients through the app. Patients can also record their symptom on the app for doctors to monitor.
Study: NCT06035146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical energy monitoring
Description: Monitoring of the mechanical energy acting on the lung parenchyma during mechanical ventilation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional mechanical ventilation
Description: The conventional procedure of mechanical ventilation controlled according to the physician's decision.
Study: NCT05164484

Intervention type: DEVICE
Group type: OTHER
Intervention: Transpulmonary thermodilution
Description: Through the analysis of the thermodilution curve recorded at the tip of an arterial catheter after the injection of a cold bolus in the venous circulation, transpulmonary thermodilution intermittently measures cardiac output.
Study: NCT06125938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tent pole technique
Description: The screw tent-pole method is an effective technique to achieve initial reconstruction of alveolar bone deficiencies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone block technique
Description: Bone block graft has been the gold standard for restoring deficient regions.
Study: NCT05070637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-touch laparoscopic radical nephrectomy
Description: We aim to determine if a laparoscopic no-touch nephrectomy with an early renal pedicle ligation can decrease CTC release during surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic radical nephrectomy
Description: Conventional laparoscopic radical nephrectomy, which implies manipulation of the kidney, opening of the Gerota's fascia, and manipulation of peri-nephric fat during dissection, and renal pedicle isolation.
Study: NCT06436898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined overground gait exoskeleton and FES applied to lower limb
Description: Gait rehabilitation for persons with stroke, with an overground exoskeleton combined with an electromyographically controlled FES applied to lower limb muscles during gait.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Overground gait exoskeleton
Description: Gait rehabilitation for persons with stroke, with an overground exoskeleton.
Study: NCT05070637

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic total nephrectomy control arm
Description: Control arm in which a laparoscopic total nephrectomy will be performed in non-cancer patients.
Study: NCT04843787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule (400mg) BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule (400mg) BID
Study: NCT05269654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injectable poly-L-lactic acid
Description: Injectable biostimulant for volume loss

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: Sham Comparator
Study: NCT04843787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule (800mg) QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule (800mg) QD
Study: NCT06097754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: Ketone ester: A total of 300g ketone ester supplementation will be provided in one of the 72h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate~Hypobaric hypoxia: 72 hours experimental protocol conducted at terrestrial altitude
Study: NCT05666063

Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory Urodynamic Study
Description: Ambulatory urodynamic study is started after spontaneous diuresis of the patients. Ambulatory monitoring time is limited to each patient's own voiding cycle. The patient and a family member are instructed on the use of the event buttons on the patient module to flag incontinence, urgency, physical activity, and water drinking. With the use of catheters attached to microcomputers attached to their shoulders, patients are free to move around and engage in activities that may cause urinary incontinence. After voiding, the residual urine volume is first measured and then urethral and rectal catheters are placed. Monitoring is terminated when the patient feels that he cannot delay the urination sensation.Questionnaires that are routinely applied in our clinic will be applied in order to objectively evaluate the symptoms. Before urodynamics, urinary tract infection, whether symptomatic or not, must be routinely excluded with a complete urinalysis and urine culture.
Study: NCT06097754

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Water, 5% sucralose (w/w), octaacetate (1 mM)~Hypobaric hypoxia: 72 hours experimental protocol conducted at terrestrial altitude
Study: NCT05279014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal timing
Description: A high-carbohydrate (1 g/kg body mass) meal to be consumed either 1.5-3 hours before or immediately after exercise. Those consuming the meal after exercise will have fasted for at least 8 hours before exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal timing
Description: A high-carbohydrate (1 g/kg body mass) meal to be consumed either 1.5-3 hours before or immediately after exercise. Those consuming the meal after exercise will have fasted for at least 8 hours before exercise.
Study: NCT05115136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxepin
Description: 25mg dose of Doxepin will be administered one time, by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: 50 mg dose of Diphenhydramine will be administered one time, by mouth
Study: NCT05599022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Stimulation
Description: Transcutaneous Magnetic Stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Stimulation
Description: Transcutaneous Magnetic Stimulation
Study: NCT05904288

Intervention type: DEVICE
Intervention: Smartwatch Garmin Vivosmart [wearable sensor]
Description: Garmin Vivo Smart is a fitness tracker, which is aimed at collecting patient's motor activity and heart rate data from embedded Inertial Movement Unit (IMU) and Photoplethismograph (PPG) sensors.

Intervention type: DEVICE
Intervention: Soturi™ [digital mobile app]
Description: Soturi software is a proprietary mobile application, for people with Parkinson's Disease (PD) designed to record symptoms, by means of self-report diary, set reminders for medication intake. Soturi™ Physical Exercise Program and Speech Exercise Program.
Study: NCT05599022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Stimulation
Description: Transcutaneous Magnetic Stimulation
Study: NCT05904288

Intervention type: OTHER
Intervention: Clinical Assessment
Description: Outpatient repeated-measures clinical evaluations, which include assessment of motor symptoms through MDS-UPDRS and ecological motor tasks, to observe changes with respect to medication intake, and changes over a 6 month period time.
Study: NCT04956328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid Tablets
Description: Obeticholic Acid：Once a day (QD) by mouth (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: UDCA：continue prestudy dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA
Description: UDCA：continue prestudy dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo